AG
BEAM icon

Artal Group’s Beam Therapeutics BEAM Stock Holding History

Artal Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,975
Closed -$264K – 100
2023
Q3 		$264K Hold
10,975
– – 0.01% 95
2023
Q2 		$350K Hold
10,975
– – 0.01% 109
2023
Q1 		$336K Buy
+10,975
New +$433K 0.02% 107

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Artal Group's BEAM Position: Q4 2023 in Review

Artal Group sold out of Beam Therapeutics (BEAM) in Q4 2023, closing a stake of 10,975 shares — an estimated $264K sold.

Artal Group first reported a position in BEAM in Q1 2023 and held it in 3 quarters. The position peaked at $350K in Q2 2023. 185 funds tracked by Wall St. Rank hold BEAM as of Q4 2023.

  • Artal Group reported no remaining Beam Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Artal Group sold 10,975 Beam Therapeutics shares in Q4 2023, an estimated $264K.
  • Artal Group first reported a position in Beam Therapeutics in Q1 2023 and held it in 3 quarters.
  • Artal Group's Beam Therapeutics position peaked at $350K in Q2 2023.
  • 185 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.